tri-1

TRi-1 is irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy

1,2,3-Tri-10(Z)-undecenoyl glycerol is a triglyceride composed of 10-undecenoic acid esterified at the sn-1, sn-2, and sn-3 positions.

1,2,3-Tri-13(E)-docosenoyl glycerol, a triacylglycerol featuring 13(E)-docosenoic acid at the \(sn-1\), \(sn-2\), and \(sn-3\) positions, transiently elevates heart triglyceride levels in weanling rats when administered as 15% of a calcium-deficient diet, with levels returning to baseline after 28 days.

1,2,3-Tri-11(Z)-eicosenoyl glycerol, a triacylglycerol with 11(Z)-eicosenoic acid at the sn-1,sn-2, and sn-3 positions, serves as an internal standard for quantifying triacylglycerols in seed and olive oils.

Tri-10(Z)-pentadecenoin (1,2,3-Tri-10(Z)-pentadecenoyl glycerol) is a triglyceride in which the sn-1, sn-2, and sn-3 positions are all esterified with 10(Z)-pentadecenoic acid.

Tri-11(E)-eicosenoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z),17(Z)-eicosatrienoin is a lipid utilized in formulating lipid nanoparticles (LNPs) for drug delivery purposes.

Tri-11(Z)-octadecenoin is a lipid used in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-10(Z)-nonadecenoin is a lipid utilized in the preparation of lipid nanoparticles (LNP) for drug delivery applications.

Tri-11(Z),14(Z)-eicosadienoin is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery.

RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1].

b-Casomorphin (1-3) Acetate is a tri-peptide with an opioid effect.

Amino-Tri-(carboxyethoxymethyl)-methane, an ADC linker and PROTAC linker, is a cleavable PEG compound utilized for the synthesis of antibody-drug conjugates (ADCs)[1] and PEG-based PROTACs[2].

Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane is a PEG-based linker compound used in the synthesis of PROTACs [1].

Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane, a PEG-derived PROTAC linker, is used for PROTAC synthesis[1].

Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) for the preparation of neolymphostin-based ADC precursors, specifically for site-specific cysteine mutant trastuzumab-A114C conjugation[1].

Tri(Amino-PEG5-amide)-amine is a polyethylene glycol (PEG) derivative used as a PEG-based proteolysis targeting chimera (PROTAC) linker to aid in the synthesis of PROTACs[1].

Tri(t-butoxycarbonylethoxymethyl) ethanol, an alkyl/ether-based PROTAC linker, is suitable for synthesizing PROTACs[1].

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine, a cleavable PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs). It is also a PEG-based PROTAC linker, specifically Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane, widely used in the synthesis of PROTACs [1].

Amino-Tri-(m-PEG4-ethoxymethyl)-methane, a PEG-based PROTAC linker, is a crucial element for synthesizing PROTACs[1].

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable one-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Tri(Amino-PEG3-amide)-amine, a polyethylene glycol (PEG)-derived linker, is utilized in the synthesis of proteolysis-targeting chimeric molecules (PROTACs)[1].

Tri(Amino-PEG4-amide)-amine is a polyethylene glycol (PEG)-based linker compound used in the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

Tri(Mal-PEG2-amide)-amine, a polyethylene glycol (PEG)-derived linker, is commonly used for synthesizing proteolysis-targeting chimeras (PROTACs)[1].